Regencell Bioscience stock jumps 11% as RGC volatility returns ahead of Tuesday’s open

Regencell Bioscience stock jumps 11% as RGC volatility returns ahead of Tuesday’s open

NEW YORK, December 30, 2025, 05:20 ET — Premarket

  • Regencell Bioscience shares closed up nearly 11% on Monday after a wide intraday swing.
  • A fresh law-firm “investigation” notice and an older DOJ-trading probe disclosure stayed in focus.
  • Traders are watching whether the move holds once regular volume returns after the opening bell.

Regencell Bioscience Holdings Ltd shares were last indicated at $23.48 in off-hours trade ahead of Tuesday’s U.S. session.

The stock ended Monday up 10.96% at $23.48, after trading as low as $19.80 and as high as $25.50, with about 723,000 shares changing hands, MarketBeat data showed. Market capitalization was listed at roughly $11.6 billion. MarketBeat

The move stood out on a day when U.S. stocks finished lower, leaving investors cautious heading into a holiday-shortened stretch. Thin liquidity can exaggerate price swings in smaller, headline-sensitive names. Reuters

Regencell itself has not posted a new press release since Oct. 31, when it said it filed its annual report on Form 20-F, the SEC annual filing used by foreign private issuers. Regencell Bioscience –

Legal headlines have circulated again in recent days. Bronstein, Gewirtz & Grossman said on Dec. 28 it was investigating potential claims on behalf of Regencell investors, an announcement that can amplify chatter without indicating any formal finding by regulators or a court. ACCESS Newswire

In its annual report, Regencell disclosed it received correspondence and a subpoena from the U.S. Department of Justice indicating an investigation into trading in its ordinary shares, following prior volatility. SEC

After-hours trading on Monday was modest, with the stock quoted at $23.48 and up about 1.75%, according to Barron’s market data. Barron’s

Regencell is a Hong Kong-based early-stage bioscience company focused on traditional Chinese medicine formulations for neurocognitive disorders, including attention deficit hyperactivity disorder and autism spectrum disorder, according to its company profile. Reuters

On Monday, the shares opened sharply lower than the prior close — a “gap down,” meaning the first trade printed below the previous session’s closing price — before reversing higher, MarketBeat said. MarketBeat

Stock Market Today

  • Undervalued TSX Stocks Trading Up to 49.5% Below Intrinsic Value
    December 30, 2025, 9:13 AM EST. Canadian markets are rewarding a diversified, cash-flow driven approach in 2026, with several TSX names trading well below their intrinsic value. The screen highlights discounts to fair value of up to 49.5%, suggesting room for multiple expansion as earnings are projected to grow faster than the market. Illustrative examples include Badger Infrastructure Solutions (BDGI) and Montage Gold (MAU), where solid cash flows underpin upside even with leverage. The analysis notes earnings growth of about 24.4% annually over the next three years, versus roughly 12% for the broader Canadian market. For investors, combining diversification with a focus on stocks with strong free cash flow and clear expansion catalysts may help navigate 2026's volatility while capturing mispricings on the TSX.
GST deadline tomorrow: CA body urges India to extend GSTR-9/9C as Goa chamber seeks late-fee waiver
Previous Story

GST deadline tomorrow: CA body urges India to extend GSTR-9/9C as Goa chamber seeks late-fee waiver

NIO stock today: Premarket ticks higher as CATL battery shift report meets 2026 demand warning
Next Story

NIO stock today: Premarket ticks higher as CATL battery shift report meets 2026 demand warning

Go toTop